Roger Brüggemann’s research interest area are in the management of invasive fungal infections, pharmacokinetics, pharmacodynamics and pharmacogenetics of antifungal agents in both humans and animals, therapeutic drug monitoring, drug-drug interactions and analytical analysis of antifungal drug in various matrices.
Additionally, he has experience in the design, conduct, analysis and reporting of single and multi-centre trials involving azole and echinocandin drugs in a wide variety of patients such as (pediatric) hematology and intensive care unit patients and healthy volunteers trials.